Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
43.2Last Year’s EPS
43.4Same Quarter Last Year
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 1.15%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a positive start to 2025 with robust growth in specialty medicines and progress in the HIV segment, supported by strategic acquisitions and shareholder returns. However, challenges in vaccine sales, tariff impacts, and Medicare Part D redesign headwinds are noted, balancing the overall outlook.Company Guidance
In the GSK Q1 2025 Results Call, the company reaffirmed its financial guidance for 2025, highlighting several key metrics. Group sales saw a 4% increase, driven by a robust 17% growth in specialty medicines. Core operating profit and core earnings per share both rose by 5%, reaching 44.9 pence. Despite a 6% decline in vaccine sales, the overall performance was in line with expectations. The company also reported cash generation from operations exceeding £1 billion, allowing further investment in growth initiatives and shareholder returns. GSK has initiated a £2 billion share buyback program and increased its dividend to 16 pence per share. Additionally, the company emphasized its commitment to innovation, with two FDA approvals secured and three more anticipated within the year. GSK's strategic focus on specialty medicines and long-acting treatments, especially in HIV and oncology, underpins its confidence in achieving sustained profitable growth, despite macroeconomic uncertainties.Strong Sales and Profit Growth
Group sales increased by 4%, core operating profit grew by 5%, and core earnings per share rose 5% to 44.9 pence, driven by specialty medicines up 17%.
Innovation and Pipeline Progress
Two out of five expected FDA product approvals for 2025 have been secured. Notable approvals include Blenrep in the UK and expected FDA decisions for Nucala COPD and depemokimab.
HIV Treatment and Prevention Growth
HIV sales grew 7%, with strong demand for Dovato, Cabenuva, and Apretude, growing 19%, 38%, and 63% respectively.
Strategic Acquisitions and Investments
Completion of the acquisition of IDRX, and the commencement of a £2 billion share buyback program.
Sustained Dividends and Shareholder Returns
Quarterly dividend increased to 16 pence, with over £0.8 billion returned to shareholders through dividends and buybacks.
---
GB:GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 30, 2025 | 1432.00p | 1483.50p | +3.60% |
| Feb 05, 2025 | 1364.64p | 1468.47p | +7.61% |
| Oct 30, 2024 | 1419.54p | 1376.02p | -3.07% |
| Jul 31, 2024 | 1494.37p | 1464.82p | -1.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GlaxoSmithKline (GB:GSK) report earnings?
GlaxoSmithKline (GB:GSK) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is GlaxoSmithKline (GB:GSK) earnings time?
GlaxoSmithKline (GB:GSK) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of GlaxoSmithKline stock?
The P/E ratio of GlaxoSmithKline is N/A.
What is GB:GSK EPS forecast?
GB:GSK EPS forecast for the fiscal quarter 2025 (Q2) is 43.2.
---